<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203311434941</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203311434941</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Concise report</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Associations between the p53 codon 72 polymorphisms and susceptibility to systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lee</surname><given-names>YH</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311434941">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203311434941"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Bae</surname><given-names>S-C</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311434941">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Choi</surname><given-names>SJ</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311434941">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ji</surname><given-names>JD</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311434941">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Song</surname><given-names>GG</given-names></name>
<xref ref-type="aff" rid="aff1-0961203311434941">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203311434941"><sup>1</sup>Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine, Korea; and <sup>2</sup>The Hospital for Rheumatic Diseases, Hanyang University Medical Center, Korea</aff>
<author-notes>
<corresp id="corresp1-0961203311434941">Young Ho Lee, Division of Rheumatology, Department of Internal Medicine, Korea University, Anam Hospital, Korea University College of Medicine, 126-1, Anam-dong 5-ga, Seongbuk-gu, Seoul 136-705, Korea Email: <email>lyhcgh@korea.ac.kr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>21</volume>
<issue>4</issue>
<fpage>430</fpage>
<lpage>437</lpage>
<history>
<date date-type="received"><day>31</day><month>10</month><year>2011</year></date>
<date date-type="accepted"><day>8</day><month>12</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><bold>Objective:</bold> The aim of this study was to determine whether the p53 codon 72 polymorphism confers susceptibility to systemic lupus erythematous (SLE) and rheumatoid arthritis (RA). <bold>Methods:</bold> A meta-analysis was conducted on the associations between the p53 codon 72 polymorphism and SLE or RA using: 1) allele contrast; 2) the recessive model; 3) the dominant model; and 4) the additive model. <bold>Results:</bold> A total of 10 studies, that is, 6 SLE and 4 RA studies, involving 1578 patients and 3138 controls were considered in the meta-analysis. Meta-analysis of the p53 codon 72 polymorphism showed no association between patients and the C allele (odds ratio (OR) = 0.834, 95% confidence interval (CI) = 0.599-1.161, <italic>p</italic> = 0.282), or between SLE and the p53 C allele (OR = 0.998, 95% CI = 0.765-1.302, <italic>p</italic> = 0.989). However, stratification by ethnicity showed an association between the p53 C allele and SLE in Asians (OR = 1.410, 95% CI = 1.044-1.906, <italic>p</italic> = 0.025), but not in Europeans (OR = 0.871, 95% CI = 0.625-1.214, <italic>p</italic> = 0.415). Furthermore, an association was found between the polymorphism and SLE in Asians using recessive and additive models. However, no association was found between RA and the p53 codon 72 polymorphism in all study subjects or in Europeans. <bold>Conclusions:</bold> This meta-analysis demonstrates that the p53 codon 72 polymorphism may confer susceptibility to SLE in Asians, but not in Europeans.</p>
</abstract>
<kwd-group>
<kwd>Systemic lupus erythematosus</kwd>
<kwd>rheumatoid arthritis</kwd>
<kwd>p53</kwd>
<kwd>polymorphism</kwd>
<kwd>meta-analysis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203311434941" sec-type="intro"><title>Introduction</title>
<p>Rheumatoid arthritis (RA) is a chronic inflammatory disease that predominantly involves synovial joints and affects up to 1% of adults worldwide.<sup><xref ref-type="bibr" rid="bibr1-0961203311434941">1</xref></sup> Human leukocyte antigen (HLA) class II molecules have been shown to be strongly associated with RA, but family studies suggest that this association accounts for only one-third of genetic susceptibility and that non-HLA genes are also involved.<sup><xref ref-type="bibr" rid="bibr2-0961203311434941">2</xref></sup> On the other hand, systemic lupus erythematosus (SLE) is a prototypic human autoimmune disease and a disorder of generalized autoimmunity. It is characterized by intense inflammation and multiple organ damage.<sup><xref ref-type="bibr" rid="bibr3-0961203311434941">3</xref></sup> Although the etiologies of RA and SLE are not fully understood, it is clear that they both have genetic components.</p>
<p>Immature self-reactive T cells are deleted or become anergic in the thymus, whereas in peripheral blood, activated lymphocytes are eliminated by apoptosis. Broken tolerance to self-antigens can result in autoimmune diseases, and apoptosis depends on the functions of many molecules, including that of p53, the tumor suppressor gene, which plays central roles in apoptosis and cell proliferation and death.<sup><xref ref-type="bibr" rid="bibr4-0961203311434941">4</xref></sup> Two common polymorphic variants of wild-type p53 have been identified,<sup><xref ref-type="bibr" rid="bibr5-0961203311434941">5</xref></sup> and these arise from a single-base-pair substitution at codon 72, where either CCC encodes proline (Pro) or CGC encodes arginin (Arg). These p53 variants have been shown to influence the function of p53 proteins in apoptosis, cell cycle control, and DNA repair.<sup><xref ref-type="bibr" rid="bibr6-0961203311434941">6</xref></sup> In addition, it has been shown that the two variants differ biochemically and biologically,<sup><xref ref-type="bibr" rid="bibr2-0961203311434941">2</xref>,<xref ref-type="bibr" rid="bibr3-0961203311434941">3</xref></sup> and that they are associated with several types of cancer.<sup><xref ref-type="bibr" rid="bibr7-0961203311434941">7</xref></sup></p>
<p>The p53 codon 72 polymorphism has also been associated with SLE and RA in some reports, but by no means in all.<sup><xref ref-type="bibr" rid="bibr8-0961203311434941">8</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr16-0961203311434941">16</xref></sup> The reasons for this disparity may be small sample sizes, low statistical power, and/or clinical heterogeneity. Therefore, in order to overcome the limitations of individual studies, resolve inconsistencies, and reduce the likelihood that random errors are responsible for false-positive or false-negative associations,<sup><xref ref-type="bibr" rid="bibr17-0961203311434941">17</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr19-0961203311434941">19</xref></sup> we turned to meta-analysis. The aim of the present study was to determine, using meta-analysis, whether the p53 codon 72 polymorphism confers susceptibility to SLE or RA.</p></sec>
<sec id="sec2-0961203311434941" sec-type="methods"><title>Methods</title>
<sec id="sec3-0961203311434941"><title>Identification of eligible studies and data extraction</title>
<p>We performed a search for studies that examined associations between the p53 polymorphism and SLE or RA. The literature was searched using the MEDLINE citation database to identify available articles in which the p53 codon 72 polymorphism was analyzed in SLE or RA. Combinations of keywords, such as ‘p53’5 ‘polymorphism’o ‘systemic lupus erythematosus’r rythe, ‘rheumatoid arthritis’h and ‘RA’ were entered as Medical Subject Heading (MeSH) components and as text words. References in identified studies were also investigated to identify additional studies not indexed by MEDLINE. Genetic association studies that determined the distributions of the p53 codon 72 genotypes in SLE, RA, and in normal controls were included. The following information was extracted from each study: author, year of publication, ethnicity of the study population, demographics, and the number of cases and controls for each p53 codon 72 genotype. Frequencies of alleles were calculated from corresponding genotype distributions.</p></sec>
<sec id="sec4-0961203311434941"><title>Evaluation of publication bias</title>
<p>Funnel plots are often used to detect publication bias. However, due to the limitations of funnel plotting, which requires a range of studies of varying sizes involving subjective judgments, we evaluated publication bias using Egger’s linear regression test,<sup><xref ref-type="bibr" rid="bibr20-0961203311434941">20</xref></sup> which measures funnel plot asymmetry using a natural logarithmic scale of odds ratios (ORs).</p></sec>
<sec id="sec5-0961203311434941"><title>Evaluations of statistical associations</title>
<p>Meta-analyses were performed using: 1) allelic contrast, 2) recessive, 3) dominant, and 4) additive models. Point estimates of risks, ORs, and 95% confidence intervals (CIs) were estimated for each study, and within- and between-study variations and heterogeneities were assessed using Cochran’s Q-statistic. This heterogeneity test assesses the null hypothesis that all studies evaluated the same effect. The effect of heterogeneity was quantified using I<sup>2</sup>, which ranges between 0 and 100%, and represents the proportion of between-study variability that can be attributed to heterogeneity rather than chance.<sup><xref ref-type="bibr" rid="bibr21-0961203311434941">21</xref></sup> I<sup>2</sup> values of 25, 50, and 75% were nominally assigned as low, moderate, and high estimates. The fixed effects model assumes that a genetic factor has a similar effect on SLE or on RA susceptibility across all studies investigated, and that observed variations among studies are caused by chance alone.<sup><xref ref-type="bibr" rid="bibr22-0961203311434941">22</xref></sup> The random effects model assumes that different studies show substantial diversity and assesses both within-study sampling errors and between-study variances.<sup><xref ref-type="bibr" rid="bibr23-0961203311434941">23</xref></sup> When study groups are homogeneous, the two models are similar. If this is not the case, the random effects model usually provides wider CIs than the fixed effects model; the random effects model is best used in the presence of significant between study heterogeneity.<sup><xref ref-type="bibr" rid="bibr23-0961203311434941">23</xref></sup> Statistical manipulations were undertaken using a Comprehensive Meta-Analysis computer program (Biosta, Englewood, NJ, USA). The power of each study was computed as the probability of detecting an association between the p53 polymorphism and diseases at a level of significance of 0.05, assuming an OR of 1.5 (small effect size). The power analysis was performed using the G*Power statistical program (<ext-link ext-link-type="uri" xlink:href="http://www.psycho.uni-duesseldorf.de/aap/projects/gpower">http://www.psycho.uni-duesseldorf.de/aap/projects/gpower</ext-link>).</p></sec></sec>
<sec id="sec6-0961203311434941" sec-type="results"><title>Results</title>
<sec id="sec7-0961203311434941"><title>Studies included in the meta-analysis</title>
<p>Sixteen studies were identified by electronic and manual searching and nine were selected for a full text review, based on the title and abstract details.<sup><xref ref-type="bibr" rid="bibr8-0961203311434941">8</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr12-0961203311434941">12</xref>,<xref ref-type="bibr" rid="bibr14-0961203311434941">14</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr16-0961203311434941">16</xref>,<xref ref-type="bibr" rid="bibr24-0961203311434941">24</xref></sup> One study was excluded because it was not a case-control study.<sup><xref ref-type="bibr" rid="bibr24-0961203311434941">24</xref></sup> One of the eligible studies contained data on three different SLE groups,<sup><xref ref-type="bibr" rid="bibr8-0961203311434941">8</xref></sup> and these were treated independently.<sup><xref ref-type="bibr" rid="bibr16-0961203311434941">16</xref>,<xref ref-type="bibr" rid="bibr25-0961203311434941">25</xref></sup> Thus, a total of 10 separate comparisons, including 6 SLE and 4 RA studies, were considered in the meta-analysis, and in total these contained 1578 patients and 3138 controls<sup><xref ref-type="bibr" rid="bibr8-0961203311434941">8</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr12-0961203311434941">12</xref>,<xref ref-type="bibr" rid="bibr14-0961203311434941">14</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr16-0961203311434941">16</xref></sup> (<xref ref-type="table" rid="table1-0961203311434941">Table 1</xref>). These 10 studies encompassed 5 European, 3 Asian, 1 African American, and 1 South American population. Ethnicity-specific meta-analysis was also conducted in the European and Asian populations. Relations between the p53 codon 72 polymorphism and SLE and RA by ethnicity are summarized in <xref ref-type="table" rid="table1-0961203311434941">Table 1</xref>. The statistical powers of these 10 studies ranged between 17.0 and 90.8% (<xref ref-type="table" rid="table1-0961203311434941">Table 1</xref>). Meta-analysis on the association between the p53 codon 72 polymorphism and the two diseases was performed when there were at least two relevant studies.
<table-wrap id="table1-0961203311434941" position="float"><label>Table 1</label><caption><p>Characteristics of the individual studies included in the meta-analysis</p></caption>
<graphic alternate-form-of="table1-0961203311434941" xlink:href="10.1177_0961203311434941-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Author (Ref)</th>
<th rowspan="2">Ethnicity</th>
<th rowspan="2">Disease</th>
<th colspan="2"><hr/>Numbers</th>
<th colspan="3">Case<hr/></th>
<th colspan="3">Control<hr/></th>
<th rowspan="2">HWE <italic>p</italic>-value</th>
<th rowspan="2">Power (%)<sup><xref ref-type="table-fn" rid="table-fn2-0961203311434941">a</xref></sup></th></tr>
<tr><th>Case</th>
<th>Control</th>
<th>GG</th>
<th>GC</th>
<th>CC</th>
<th>GG</th>
<th>GC</th>
<th>CC</th></tr></thead>
<tbody align="left">
<tr>
<td>Onel-1 et al. 2009<sup><xref ref-type="bibr" rid="bibr8-0961203311434941">8</xref></sup></td>
<td>African American</td>
<td>SLE</td>
<td>57</td>
<td>188</td>
<td>12</td>
<td>29</td>
<td>16</td>
<td>40</td>
<td>83</td>
<td>65</td>
<td>0.16</td>
<td>34.7</td></tr>
<tr>
<td>Onel-2 et al. 2009<sup><xref ref-type="bibr" rid="bibr8-0961203311434941">8</xref></sup></td>
<td>European</td>
<td>SLE</td>
<td>169</td>
<td>285</td>
<td>84</td>
<td>69</td>
<td>16</td>
<td>150</td>
<td>123</td>
<td>12</td>
<td>0.03</td>
<td>56.7</td></tr>
<tr>
<td>Onel-3 et al. 2009<sup><xref ref-type="bibr" rid="bibr8-0961203311434941">8</xref></sup></td>
<td>Asian</td>
<td>SLE</td>
<td>44</td>
<td>212</td>
<td>16</td>
<td>19</td>
<td>9</td>
<td>70</td>
<td>114</td>
<td>28</td>
<td>0.08</td>
<td>36.0</td></tr>
<tr>
<td>Piotrowski et al. 2008<sup><xref ref-type="bibr" rid="bibr9-0961203311434941">9</xref></sup></td>
<td>European</td>
<td>SLE</td>
<td>155</td>
<td>150</td>
<td>75</td>
<td>66</td>
<td>14</td>
<td>50</td>
<td>80</td>
<td>20</td>
<td>0.17</td>
<td>41.6</td></tr>
<tr>
<td>Sanchez et al. 2006<sup><xref ref-type="bibr" rid="bibr10-0961203311434941">10</xref></sup></td>
<td>European</td>
<td>SLE</td>
<td>513</td>
<td>567</td>
<td>369</td>
<td>128</td>
<td>16</td>
<td>381</td>
<td>163</td>
<td>23</td>
<td>0.29</td>
<td>90.8</td></tr>
<tr>
<td>Lee et al. 2005<sup><xref ref-type="bibr" rid="bibr11-0961203311434941">11</xref></sup></td>
<td>Asian</td>
<td>SLE</td>
<td>90</td>
<td>114</td>
<td>20</td>
<td>42</td>
<td>28</td>
<td>37</td>
<td>60</td>
<td>17</td>
<td>0.35</td>
<td>29.8</td></tr>
<tr>
<td>Moodley et al. 2010<sup><xref ref-type="bibr" rid="bibr1-0961203311434941">1</xref></sup><sup><xref ref-type="bibr" rid="bibr2-0961203311434941">2</xref></sup></td>
<td>South African</td>
<td>RA</td>
<td>50</td>
<td>50</td>
<td>6</td>
<td>23</td>
<td>21</td>
<td>2</td>
<td>17</td>
<td>31</td>
<td>0.86</td>
<td>17.0</td></tr>
<tr>
<td>Assmann et al. 2009<sup><xref ref-type="bibr" rid="bibr1-0961203311434941">1</xref></sup><sup><xref ref-type="bibr" rid="bibr6-0961203311434941">6</xref></sup></td>
<td>European</td>
<td>RA</td>
<td>215</td>
<td>258</td>
<td>131</td>
<td>69</td>
<td>15</td>
<td>28</td>
<td>196</td>
<td>34</td>
<td>6.5E-17</td>
<td>58.5</td></tr>
<tr>
<td>Macchioni et al. 2007<sup><xref ref-type="bibr" rid="bibr1-0961203311434941">1</xref></sup><sup><xref ref-type="bibr" rid="bibr4-0961203311434941">4</xref></sup></td>
<td>European</td>
<td>RA</td>
<td>171</td>
<td>200</td>
<td>80</td>
<td>74</td>
<td>17</td>
<td>97</td>
<td>84</td>
<td>19</td>
<td>0.89</td>
<td>48.7</td></tr>
<tr>
<td>Lee et al. 2001<sup><xref ref-type="bibr" rid="bibr1-0961203311434941">1</xref></sup><sup><xref ref-type="bibr" rid="bibr5-0961203311434941">5</xref></sup></td>
<td>Asian</td>
<td>RA</td>
<td>114</td>
<td>114</td>
<td>38</td>
<td>58</td>
<td>18</td>
<td>37</td>
<td>60</td>
<td>17</td>
<td>0.35</td>
<td>32.7</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203311434941"><p>Ref: reference; HWE: Hardy-Weinberg equilibrium; SLE: systemic lupus erythematous; RA: rheumatoid arthritis.</p></fn>
<fn id="table-fn2-0961203311434941"><label>a</label><p>Assuming an odds ratio of 1.5 (small effect size) at a significance level of 0.05.</p></fn></table-wrap-foot>
</table-wrap></p></sec>
<sec id="sec8-0961203311434941"><title>Frequencies of the C allele of the p53 codon 72 polymorphism in different ethnic groups</title>
<p>The mean frequency of the C allele of the p53 codon 72 polymorphism was 35.3% among all normal controls, and Europeans had a lower C allele prevalence than the other ethnic groups. Again, among normal controls, the frequencies of the C allele in the European, Asian, African American, and South American populations were 29.5, 40.7, 56.7, and 79.0%, respectively (<xref ref-type="table" rid="table2-0961203311434941">Table 2</xref>).
<table-wrap id="table2-0961203311434941" position="float"><label>Table 2</label><caption><p>Prevalence of the C allele of the p53 codon 72 polymorphism</p></caption>
<graphic alternate-form-of="table2-0961203311434941" xlink:href="10.1177_0961203311434941-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Population</th>
<th rowspan="2">No. of studies</th>
<th colspan="2">Numbers<hr/></th>
<th colspan="2">C allele (%)<hr/></th></tr>
<tr><th>Case</th>
<th>Control</th>
<th>Case</th>
<th>Control</th></tr></thead>
<tbody align="left">
<tr>
<td>European</td>
<td>5</td>
<td>1223</td>
<td>1460</td>
<td>23.0</td>
<td>29.5</td></tr>
<tr>
<td>Asian</td>
<td>3</td>
<td>248</td>
<td>440</td>
<td>46.2</td>
<td>40.7</td></tr>
<tr>
<td>African American</td>
<td>1</td>
<td>57</td>
<td>188</td>
<td>53.5</td>
<td>56.7</td></tr>
<tr>
<td>South American</td>
<td>1</td>
<td>50</td>
<td>50</td>
<td>65</td>
<td>79</td></tr>
<tr>
<td>Overall</td>
<td>10</td>
<td>1578</td>
<td>2138</td>
<td>29.06</td>
<td>35.3</td></tr>
</tbody>
</table>
</table-wrap></p></sec>
<sec id="sec9-0961203311434941"><title>Heterogeneity and publication bias</title>
<p>In SLE, no between-study heterogeneity was found during meta-analyses of the p53 polymorphism in Asians, but some heterogeneity was found in the meta-analyses of the p53 polymorphism in all study subjects and in Europeans. In RA, some heterogeneity was found in the meta-analyses of the p53 polymorphism in all study subjects overall and in Europeans. However, Egger’s regression test showed no evidence of publication bias (Egger’s regression test <italic>p</italic>-values &gt;0.1). The distributions of genotypes in normal control groups were not consistent with the Hardy-Weinberg equilibrium (HWE) in one study on RA<sup><xref ref-type="bibr" rid="bibr16-0961203311434941">16</xref></sup> and SLE.<sup><xref ref-type="bibr" rid="bibr8-0961203311434941">8</xref></sup> Deviation from the HWE among controls implies potential bias during control selection or genotyping errors. However, excluding these studies did not materially affect our meta-analysis results regarding associations between the p53 codon 72 polymorphism in SLE and RA.</p></sec>
<sec id="sec10-0961203311434941"><title>Meta-analysis of the relation between the p53 codon 72 polymorphism and SLE and RA susceptibilities</title>
<p>A summary of meta-analysis findings concerning associations between the p53 polymorphism and SLE and RA is shown in <xref ref-type="table" rid="table3-0961203311434941">Table 3</xref>. Meta-analysis of the p53 polymorphism showed no association between SLE or RA and the p53 C allele in all study subjects (OR = 0.834, 95% CI = 0.599–1.161, <italic>p</italic> = 0.282) (<xref ref-type="fig" rid="fig1-0961203311434941">Figure 1</xref>, <xref ref-type="table" rid="table3-0961203311434941">Table 3</xref>), and stratification by ethnicity indicated no association between the p53 C allele and SLE or RA in Europeans. However, associations were found between the p53 C allele and SLE and RA and in Asians. Furthermore, associations were found between the p53 polymorphism and SLERA and in Asians using the recessive and additive models (<xref ref-type="table" rid="table3-0961203311434941">Table 3</xref>).
<fig id="fig1-0961203311434941" position="float"><label>Figure 1</label><caption><p>ORs and 95% CIs of individual studies and pooled data for the association between the C allele of the p53 codon 72 polymorphism in all study subjects.</p></caption><graphic xlink:href="10.1177_0961203311434941-fig1.tif"/></fig>
<table-wrap id="table3-0961203311434941" position="float"><label>Table 3</label><caption><p>Meta-analysis of the associations between the p53 codon 72 polymorphism and SLE and RA</p></caption>
<graphic alternate-form-of="table3-0961203311434941" xlink:href="10.1177_0961203311434941-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Polymorphism</th>
<th rowspan="2">Population</th>
<th rowspan="2">No. of studies</th>
<th colspan="3">Test of association<hr/></th>
<th colspan="3">Test of heterogeneity<hr/></th></tr>
<tr><th>OR</th>
<th>95% CI</th>
<th><italic>p</italic>-value</th>
<th>Model</th>
<th><italic>p</italic>-value</th>
<th><italic>I<sup>2</sup></italic></th></tr></thead>
<tbody align="left">
<tr>
<td rowspan="4">P53 C vs. G</td>
<td>Overall</td>
<td>10</td>
<td>0.834</td>
<td>0.599–1.161</td>
<td>0.282</td>
<td>R</td>
<td>0.000</td>
<td>89.1</td></tr>
<tr>
<td>Overall in HWE</td>
<td>8</td>
<td>0.924</td>
<td>0.742–1.149</td>
<td>0.475</td>
<td>R</td>
<td>0.007</td>
<td>64.2</td></tr>
<tr>
<td>European</td>
<td>5</td>
<td>0.722</td>
<td>0.439–1.187</td>
<td>0.199</td>
<td>R</td>
<td>0.000</td>
<td>93.3</td></tr>
<tr>
<td>Asian</td>
<td>3</td>
<td>1.232</td>
<td>0.974–1.557</td>
<td>0.081</td>
<td>F</td>
<td>0.130</td>
<td>51.0</td></tr>
<tr>
<td rowspan="4">CC vs. GC + CC(Recess ive)</td>
<td>Overall</td>
<td>10</td>
<td>0.983</td>
<td>0.674–1.432</td>
<td>0.927</td>
<td>R</td>
<td>0.003</td>
<td>64.3</td></tr>
<tr>
<td>Overall in HWE</td>
<td>8</td>
<td>0.972</td>
<td>0.665–1.420</td>
<td>0.882</td>
<td>R</td>
<td>0.027</td>
<td>55.7</td></tr>
<tr>
<td>European</td>
<td>5</td>
<td>0.884</td>
<td>0.534–1.463</td>
<td>0.632</td>
<td>R</td>
<td>0.031</td>
<td>62.3</td></tr>
<tr>
<td>Asian</td>
<td>3</td>
<td>1.698</td>
<td>1.509–2.599</td>
<td>0.015</td>
<td>F</td>
<td>0.221</td>
<td>33.7</td></tr>
<tr>
<td rowspan="4">CC + GC vs. CC (Dominant)</td>
<td>Overall</td>
<td>10</td>
<td>0.687</td>
<td>0.403–1.171</td>
<td>0.168</td>
<td>R</td>
<td>0.000</td>
<td>91.3</td></tr>
<tr>
<td>Overall in HWE</td>
<td>8</td>
<td>0.880</td>
<td>0.690–1.123</td>
<td>0.304</td>
<td>R</td>
<td>0.112</td>
<td>40.0</td></tr>
<tr>
<td>European</td>
<td>5</td>
<td>0.531</td>
<td>0.233–1.210</td>
<td>0.132</td>
<td>R</td>
<td>0.000</td>
<td>95.6</td></tr>
<tr>
<td>Asian</td>
<td>3</td>
<td>1.112</td>
<td>0.780–1.586</td>
<td>0.257</td>
<td>F</td>
<td>0.294</td>
<td>18.3</td></tr>
<tr>
<td rowspan="4">CC vs. GG (Additive)</td>
<td>Overall</td>
<td>10</td>
<td>0.790</td>
<td>0.411–1.519</td>
<td>0.480</td>
<td>R</td>
<td>0.000</td>
<td>84.2</td></tr>
<tr>
<td>Overall in HWE</td>
<td>8</td>
<td>0.430</td>
<td>0.605–1.471</td>
<td>0.796</td>
<td>R</td>
<td>0.029</td>
<td>55.1</td></tr>
<tr>
<td>European</td>
<td>5</td>
<td>0.604</td>
<td>0.216–1.686</td>
<td>0.336</td>
<td>R</td>
<td>0.000</td>
<td>89.8</td></tr>
<tr>
<td>Asian</td>
<td>3</td>
<td>1.656</td>
<td>1.018–2.692</td>
<td>0.042</td>
<td>F</td>
<td>0.163</td>
<td>44.8</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203311434941"><p>SLE: systemic lupus erythematous; RA: rheumatoid arthritis; OR: odds ratio; CI: confidence interval; F: fixed model; R: random model; HWE: Hardy-Weinberg equilibrium.</p></fn></table-wrap-foot>
</table-wrap></p></sec>
<sec id="sec11-0961203311434941"><title>Meta-analysis of the p53 codon 72 polymorphism and SLE susceptibility</title>
<p>Meta-analysis revealed no association between the p53 C allele and SLE in all study subjects (OR = 0.998, 95% CI = 0.765, 95% CI<italic>p</italic> = 0.989) (<xref ref-type="fig" rid="fig2-0961203311434941">Figure 2</xref>, <xref ref-type="table" rid="table4-0961203311434941">Table 4</xref>). To evaluate race-specific effects, we divided study subjects by ethnicity. This stratification indicated an association between the p53 C allele and SLE in Asians (OR = 1.410, 95% CI = 1.044, 95% CI<italic>p</italic> = 0.025), but no association in Europeans (OR = 0.871, 95% CI = 0.625, 95% CI<italic>p</italic> = 0.415) (<xref ref-type="table" rid="table4-0961203311434941">Table 4</xref>). Furthermore, an association was found between the polymorphism and SLE in Asians using the recessive and additive models. However, no association was found between the polymorphism and SLE in Europeans using the recessive, dominant, or additive models (<xref ref-type="table" rid="table4-0961203311434941">Table 4</xref>).
<fig id="fig2-0961203311434941" position="float"><label>Figure 2</label><caption><p>ORs and 95% CIs of individual studies and pooled data for associations between the C allele of the p53 codon 72 polymorphism and SLE or RA.</p></caption><graphic xlink:href="10.1177_0961203311434941-fig2.tif"/></fig>
<table-wrap id="table4-0961203311434941" position="float"><label>Table 4</label><caption><p>Meta-analysis of the association between the p53 codon 72 polymorphism and SLE</p></caption>
<graphic alternate-form-of="table4-0961203311434941" xlink:href="10.1177_0961203311434941-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Polymorphism</th>
<th rowspan="2">Population</th>
<th rowspan="2">No. of studies</th>
<th colspan="3">Test of association<hr/></th>
<th colspan="3">Test of heterogeneity<hr/></th></tr>
<tr><th>OR</th>
<th>95% CI</th>
<th><italic>p</italic>-value</th>
<th>Model</th>
<th><italic>p</italic>-value</th>
<th><italic>I</italic><xref ref-type="bibr" rid="bibr2-0961203311434941"><italic><sup>2</sup></italic></xref></th></tr></thead>
<tbody align="left">
<tr>
<td rowspan="4">P53 C vs. G</td>
<td>Overall</td>
<td>6</td>
<td>0.998</td>
<td>0.765–1.302</td>
<td>0.989</td>
<td>R</td>
<td>0.003</td>
<td>72.4</td></tr>
<tr>
<td>Overall in HWE</td>
<td>5</td>
<td>0.955</td>
<td>0.703–1.296</td>
<td>0.766</td>
<td>R</td>
<td>0.005</td>
<td>73.1</td></tr>
<tr>
<td>European</td>
<td>3</td>
<td>0.871</td>
<td>0.625–1.214</td>
<td>0.415</td>
<td>R</td>
<td>0.017</td>
<td>75.5</td></tr>
<tr>
<td>Asian</td>
<td>2</td>
<td>1.410</td>
<td>1.044–1.906</td>
<td>0.025</td>
<td>F</td>
<td>0.146</td>
<td>52.5</td></tr>
<tr>
<td rowspan="4">CC vs. GC + CC (Recessive)</td>
<td>Overall</td>
<td>6</td>
<td>1.226</td>
<td>0.736–2.043</td>
<td>0.433</td>
<td>R</td>
<td>0.009</td>
<td>67.3</td></tr>
<tr>
<td>Overall in HWE</td>
<td>5</td>
<td>1.082</td>
<td>0.632–1.853</td>
<td>0.774</td>
<td>R</td>
<td>0.020</td>
<td>65.8</td></tr>
<tr>
<td>European</td>
<td>3</td>
<td>1.035</td>
<td>0.481–2.226</td>
<td>0.930</td>
<td>R</td>
<td>0.032</td>
<td>71.0</td></tr>
<tr>
<td>Asian</td>
<td>2</td>
<td>2.176</td>
<td>1.284–3.688</td>
<td>0.004</td>
<td>F</td>
<td>0.442</td>
<td>0</td></tr>
<tr>
<td rowspan="4">CC + GC vs. CC (Dominant)</td>
<td>Overall</td>
<td>6</td>
<td>0.908</td>
<td>0.683–1.209</td>
<td>0.510</td>
<td>R</td>
<td>0.056</td>
<td>53.5</td></tr>
<tr>
<td>Overall in HWE</td>
<td>5</td>
<td>0.862</td>
<td>0.616–1.207</td>
<td>0.387</td>
<td>R</td>
<td>0.071</td>
<td>53.7</td></tr>
<tr>
<td>European</td>
<td>3</td>
<td>0.798</td>
<td>0.556–1.146</td>
<td>0.222</td>
<td>R</td>
<td>0.158</td>
<td>49.7</td></tr>
<tr>
<td>Asian</td>
<td>2</td>
<td>1.232</td>
<td>0.776–1.957</td>
<td>0.376</td>
<td>F</td>
<td>0.158</td>
<td>49.7</td></tr>
<tr>
<td rowspan="4">CC vs. GG (Additive)</td>
<td>Overall</td>
<td>6</td>
<td>1.171</td>
<td>0.647–2.120</td>
<td>0.603</td>
<td>R</td>
<td>0.005</td>
<td>70.1</td></tr>
<tr>
<td>Overall in HWE</td>
<td>5</td>
<td>1.014</td>
<td>0.539–1.909</td>
<td>0.965</td>
<td>R</td>
<td>0.013</td>
<td>68.4</td></tr>
<tr>
<td>European</td>
<td>3</td>
<td>0.918</td>
<td>0.372–2.266</td>
<td>0.853</td>
<td>R</td>
<td>0.011</td>
<td>77.7</td></tr>
<tr>
<td>Asian</td>
<td>2</td>
<td>2.178</td>
<td>1.183–4.011</td>
<td>0.012</td>
<td>F</td>
<td>0.299</td>
<td>33.9</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0961203311434941"><p>SLE: systemic lupus erythematous; OR: odds ratio; CI: confidence interval; F: fixed model; R: random model; HWE Hardy-Weinberg equilibrium.</p></fn></table-wrap-foot>
</table-wrap></p></sec>
<sec id="sec12-0961203311434941"><title>Meta-analysis of the p53 codon 72 polymorphism and RA susceptibility</title>
<p>No association between the p53 polymorphism and RA was found using the allele contrast, recessive, dominant, or additive models in all study subjects or European, respectively (<xref ref-type="table" rid="table5-0961203311434941">Table 5</xref>).
<table-wrap id="table5-0961203311434941" position="float"><label>Table 5</label><caption><p>Meta-analysis of the association between the p53 codon 72 polymorphism and RA</p></caption>
<graphic alternate-form-of="table5-0961203311434941" xlink:href="10.1177_0961203311434941-table5.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Polymorphism</th>
<th rowspan="2">Population</th>
<th rowspan="2">No. of studies</th>
<th colspan="3">Test of association<hr/></th>
<th colspan="3">Test of heterogeneity<hr/></th></tr>
<tr><th>OR</th>
<th>95% CI</th>
<th><italic>p</italic>-value</th>
<th>Model</th>
<th><italic>p</italic>-value</th>
<th><italic>I</italic><xref ref-type="bibr" rid="bibr2-0961203311434941"><italic><sup>2</sup></italic></xref></th></tr></thead>
<tbody align="left">
<tr>
<td rowspan="3">P53 C vs. G</td>
<td>Overall</td>
<td>4</td>
<td>0.623</td>
<td>0.302–1.284</td>
<td>0.199</td>
<td>R</td>
<td>0.000</td>
<td>93.5</td></tr>
<tr>
<td>Overall in HWE</td>
<td>3</td>
<td>0.940</td>
<td>0.751–1.175</td>
<td>0.585</td>
<td>F</td>
<td>0.101</td>
<td>56.3</td></tr>
<tr>
<td>European</td>
<td>2</td>
<td>0.547</td>
<td>0.152–1.963</td>
<td>0.355</td>
<td>R</td>
<td>0.000</td>
<td>97.2</td></tr>
<tr>
<td rowspan="3">CC vs. GC + CC(Recess ive)</td>
<td>Overall</td>
<td>4</td>
<td>0.709</td>
<td>0.499–1.009</td>
<td>0.056</td>
<td>F</td>
<td>0.167</td>
<td>40.7</td></tr>
<tr>
<td>Overall in HWE</td>
<td>3</td>
<td>0.832</td>
<td>0.545–1.270</td>
<td>0.393</td>
<td>F</td>
<td>0.194</td>
<td>38.9</td></tr>
<tr>
<td>European</td>
<td>2</td>
<td>0.700</td>
<td>0.438–1.117</td>
<td>0.135</td>
<td>F</td>
<td>0.114</td>
<td>59.8</td></tr>
<tr>
<td rowspan="3">CC + GC vs. CC (Dominant)</td>
<td>Overall</td>
<td>4</td>
<td>0.402</td>
<td>0.093–1.746</td>
<td>0.224</td>
<td>R</td>
<td>0.000</td>
<td>96.0</td></tr>
<tr>
<td>Overall in HWE</td>
<td>3</td>
<td>0.984</td>
<td>0.713–1.319</td>
<td>0.923</td>
<td>F</td>
<td>0.350</td>
<td>4.69</td></tr>
<tr>
<td>European</td>
<td>2</td>
<td>0.290</td>
<td>0.222–3.777</td>
<td>0.345</td>
<td>R</td>
<td>0.000</td>
<td>98.4</td></tr>
<tr>
<td rowspan="3">CC vs. GG (Additive)</td>
<td>Overall</td>
<td>4</td>
<td>0.407</td>
<td>0.105–1.568</td>
<td>0.191</td>
<td>R</td>
<td>0.000</td>
<td>89.2</td></tr>
<tr>
<td>Overall in HWE</td>
<td>3</td>
<td>0.922</td>
<td>0.553–1.535</td>
<td>0.754</td>
<td>F</td>
<td>0.232</td>
<td>31.5</td></tr>
<tr>
<td>European</td>
<td>2</td>
<td>0.320</td>
<td>0.029–3.508</td>
<td>0.351</td>
<td>R</td>
<td>0.000</td>
<td>95.4</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0961203311434941"><p>RA: rheumatoid arthritis; OR: odds ratio; CI: confidence interval; F: fixed model; R: random model; HWE: Hardy-Weinberg equilibrium.</p></fn></table-wrap-foot>
</table-wrap></p></sec></sec>
<sec id="sec13-0961203311434941" sec-type="discussion"><title>Discussion</title>
<p>Although association studies provide a powerful means of identifying genetic factors that confer susceptibility to autoimmune diseases like SLE and RA, most reported association studies are underpowered in terms of detecting modest genetic effects that underlie susceptibilities to common diseases.<sup><xref ref-type="bibr" rid="bibr26-0961203311434941">26</xref></sup> This results in inconsistent findings due to a false positive, false negative, or true variability in associations. Meta-analysis integrates previous research, and thus increases statistical power and resolution by pooling the results of independent analyses.<sup><xref ref-type="bibr" rid="bibr27-0961203311434941">27</xref></sup> This provides a means of overcoming the small sample size problem and the often inadequate statistical powers of genetic studies on complex traits.</p>
<p>Although the multifactorial natures of SLE and RA are well recognized, genetic factors are considered to be strong determinants of these diseases, and thus researchers have been encouraged to search for the genes responsible. p53 is important for cell growth control, DNA repair, and apoptosis,<sup><xref ref-type="bibr" rid="bibr6-0961203311434941">6</xref></sup> and mutation of p53 can cause loss of cell cycle control, uncontrolled proliferation, and, in some circumstances, tumor growth. The p53 codon 72 polymorphism is located in the praline-rich domain of p53, which is needed to fully induce apoptosis. Furthermore, genetic variants at codon 72 have been shown to influence the function of the p53 protein in cell cycle control, apoptosis, and DNA repair. In addition, the variants of the p53 codon 72 polymorphism are functionally distinct, and this difference might influence susceptibility to cancers and autoimmune diseases. In particular, the Arg form of the p53 codon 72 polymorphism is significantly more efficient than the Pro form at inducing apoptosis, whereas the Pro form appears to induce a higher level of G1 cell cycle arrest than the Arg form.<sup><xref ref-type="bibr" rid="bibr28-0961203311434941">28</xref></sup> It has also been shown that the p53 codon 72 polymorphism is associated with several kinds of cancers and prognosis.<sup><xref ref-type="bibr" rid="bibr29-0961203311434941">29</xref></sup></p>
<p>Previously, we reported an association between the p53 codon 72 polymorphism and SLE.<sup><xref ref-type="bibr" rid="bibr11-0961203311434941">11</xref></sup> Specifically, we found significant differences for the genotypes and alleles of the p53 codon 72 polymorphism between SLE patients and controls. In a previous study, we found that the frequencies of the Pro allele and of the homogeneous Pro/Pro genotype were significantly higher in SLE patients than controls.<sup><xref ref-type="bibr" rid="bibr11-0961203311434941">11</xref></sup> In the present study, our meta-analysis showed no association between the p53 codon 72 polymorphism and RA in all study subjects or in Europeans, but a significant association between the p53 codon 72 polymorphism with SLE in Asians, in whom the C allele is the risk factor with an OR of 1.410 (95% CI = 1.044–1.906, <italic>p</italic> = 0.025). Furthermore, meta-analysis using the recessive and additive models showed a significant association between the p53 codon 72 polymorphism and SLE in Asians. The association observed between the p53 codon 72 polymorphism and the risks of SLE in this meta-analysis suggest that this polymorphism is a risk factor for SLE in Asians.</p>
<p>It is known that the Pro variant of the p53 codon 72 polymorphism is less efficient at inducing apoptosis than the Arg variant,<sup><xref ref-type="bibr" rid="bibr6-0961203311434941">6</xref></sup> and the dysregulation of apoptosis has been proposed to contribute to the pathogenesis of SLE. In the present study, we observed an over-representation of the Pro allele in SLE compared with the controls. We suggest that the association between the Pro allele of the p53 codon 72 and SLE susceptibility might be due to less efficient apoptosis of the Pro allele. However, our results should be interpreted with caution because of the limited number of studies included in this meta-analysis, which restricted further subgroup analyses. Furthermore, the relative importance of the p53 polymorphisms during the developments of SLE and RA may vary between ethnic groups, but we were unable to perform ethnic-specific meta-analysis in Asian or South African RA patients or in African American SLE patients due to limited data.</p>
<p>The present study has some limitations that require consideration. First, heterogeneity and confounding factors might have distorted the meta-analysis, and as such might have publication bias; studies that produced negative results may not have been published or may have been missed. Despite our use of Egger’s regression test, we cannot eliminate the possibility of bias. Second, this meta-analysis included data from European and Asian patients, and thus our results are only applicable to these ethnic groups. Third, the p53 codon 72 polymorphism may also be associated with the severities of SLE and RA. Piotrowski et al. showed the presence of an association between the CC genotype of the p53 codon 72 polymorphism and morbidity in SLE, such as fever or anti-Scl-70 antibody production.<sup><xref ref-type="bibr" rid="bibr9-0961203311434941">9</xref></sup> In addition, Macchioni et al. showed an association between the p53 codon 72 polymorphism and joint erosion in RA.<sup><xref ref-type="bibr" rid="bibr14-0961203311434941">14</xref></sup> However, the small amount of data available did not allow us to perform meta-analysis on the association between the p53 codon 72 polymorphisms and disease severity. Finally, the number of studies was too small to conclude the association between the p53 polymorphism and diseases, especially in different ethnic groups. Actually, only two p53 polymorphism studies were conducted in Asian SLE patients<sup><xref ref-type="bibr" rid="bibr8-0961203311434941">8</xref>,<xref ref-type="bibr" rid="bibr11-0961203311434941">11</xref></sup> and only one in Asian RA patients.<sup><xref ref-type="bibr" rid="bibr15-0961203311434941">15</xref></sup></p>
<p>To summarize, this meta-analysis suggests that the p53 codon 72 polymorphism confers susceptibility to SLE in Asians, but not in Europeans. However, no association was found between the p53 codon 72 polymorphism and susceptibility to RA. These findings suggest that further investigations be conducted on associations between p53 polymorphisms and SLE and RA susceptibility in different ethnic groups. Larger scale studies in different ethnic populations are required to explore the role of polymorphisms of the p53 gene in the pathogenesis of SLE and RA.</p></sec>
</body>
<back>
<sec id="sec4-0961203311434106"><title>Funding</title>
<p>This study is supported by a grant from the Korea Healthcare Technology R&amp;D Project, Ministry of Health and Welfare, Republic of Korea (A102065).</p></sec>
<sec id="sec14-0961203311434941"><title>Conflict of interest statement</title>
<p>The authors have no financial and non-financial conflicts of interest to declare.</p></sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203311434941"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harris</surname><given-names>ED</given-names><suffix>Jr</suffix></name></person-group>. <article-title>Rheumatoid arthritis. Pathophysiology and implications for therapy</article-title>. <source>N Engl J Med</source> <year>1990</year>; <volume>322</volume>: <fpage>1277</fpage>–<lpage>1289</lpage>.</citation></ref>
<ref id="bibr2-0961203311434941"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>SJ</given-names></name><name><surname>Rho</surname><given-names>YH</given-names></name><name><surname>Ji</surname><given-names>JD</given-names></name><name><surname>Song</surname><given-names>GG</given-names></name><name><surname>Lee</surname><given-names>YH</given-names></name></person-group>. <article-title>Genome scan meta-analysis of rheumatoid arthritis</article-title>. <source>Rheumatology (Oxford)</source> <year>2006</year>; <volume>45</volume>: <fpage>166</fpage>–<lpage>170</lpage>.</citation></ref>
<ref id="bibr3-0961203311434941"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Nath</surname><given-names>SK</given-names></name></person-group>. <article-title>Systemic lupus erythematosus susceptibility loci defined by genome scan meta-analysis</article-title>. <source>Hum Genet</source> <year>2005</year>; <volume>118</volume>: <fpage>434</fpage>–<lpage>443</lpage>.</citation></ref>
<ref id="bibr4-0961203311434941"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>AJ</given-names></name></person-group>. <article-title>p53, the cellular gatekeeper for growth and division</article-title>. <source>Cell</source> <year>1997</year>; <volume>88</volume>: <fpage>323</fpage>–<lpage>331</lpage>.</citation></ref>
<ref id="bibr5-0961203311434941"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matlashewski</surname><given-names>GJ</given-names></name><name><surname>Tuck</surname><given-names>S</given-names></name><name><surname>Pim</surname><given-names>D</given-names></name><name><surname>Lamb</surname><given-names>P</given-names></name><name><surname>Schneider</surname><given-names>J</given-names></name><name><surname>Crawford</surname><given-names>LV</given-names></name></person-group>. <article-title>Primary structure polymorphism at amino acid residue 72 of human p53</article-title>. <source>Mol Cell Biol</source> <year>1987</year>; <volume>7</volume>: <fpage>961</fpage>–<lpage>963</lpage>.</citation></ref>
<ref id="bibr6-0961203311434941"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pim</surname><given-names>D</given-names></name><name><surname>Banks</surname><given-names>L</given-names></name></person-group>. <article-title>p53 polymorphic variants at codon 72 exert different effects on cell cycle progression</article-title>. <source>Int J Cancer</source> <year>2004</year>; <volume>108</volume>: <fpage>196</fpage>–<lpage>199</lpage>.</citation></ref>
<ref id="bibr7-0961203311434941"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koushik</surname><given-names>A</given-names></name><name><surname>Platt</surname><given-names>RW</given-names></name><name><surname>Franco</surname><given-names>EL</given-names></name></person-group>. <article-title>p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> <year>2004</year>; <volume>13</volume>: <fpage>11</fpage>–<lpage>22</lpage>.</citation></ref>
<ref id="bibr8-0961203311434941"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Onel</surname><given-names>KB</given-names></name><name><surname>Huo</surname><given-names>D</given-names></name><name><surname>Hastings</surname><given-names>D</given-names></name><name><surname>Fryer-Biggs</surname><given-names>J</given-names></name><name><surname>Crow</surname><given-names>MK</given-names></name><name><surname>Onel</surname><given-names>K</given-names></name></person-group>. <article-title>Lack of association of the TP53 Arg72Pro SNP and the MDM2 SNP309 with systemic lupus erythematosus in Caucasian, African American, and Asian children and adults</article-title>. <source>Lupus</source> <year>2009</year>; <volume>18</volume>: <fpage>61</fpage>–<lpage>66</lpage>.</citation></ref>
<ref id="bibr9-0961203311434941"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piotrowski</surname><given-names>P</given-names></name><name><surname>Lianeri</surname><given-names>M</given-names></name><name><surname>Mostowska</surname><given-names>M</given-names></name><name><surname>Wudarski</surname><given-names>M</given-names></name><name><surname>Chwalinska-Sadowska</surname><given-names>H</given-names></name><name><surname>Jagodzinski</surname><given-names>PP</given-names></name></person-group>. <article-title>Contribution of polymorphism in codon 72 of p53 gene to systemic lupus erythematosus in Poland</article-title>. <source>Lupus</source> <year>2008</year>; <volume>17</volume>: <fpage>148</fpage>–<lpage>151</lpage>.</citation></ref>
<ref id="bibr10-0961203311434941"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sanchez</surname><given-names>E</given-names></name><name><surname>Sabio</surname><given-names>JM</given-names></name><name><surname>Callejas</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Study of a functional polymorphism in the p53 gene in systemic lupus erythematosus: lack of replication in a Spanish population</article-title>. <source>Lupus</source> <year>2006</year>; <volume>15</volume>: <fpage>658</fpage>–<lpage>661</lpage>.</citation></ref>
<ref id="bibr11-0961203311434941"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Rho</surname><given-names>YH</given-names></name><name><surname>Choi</surname><given-names>SJ</given-names></name><name><surname>Ji</surname><given-names>JD</given-names></name><name><surname>Song</surname><given-names>GG</given-names></name></person-group>. <article-title>The functional p53 codon 72 polymorphism is associated with systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2005</year>; <volume>14</volume>: <fpage>842</fpage>–<lpage>845</lpage>.</citation></ref>
<ref id="bibr12-0961203311434941"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moodley</surname><given-names>D</given-names></name><name><surname>Mody</surname><given-names>GM</given-names></name><name><surname>Chuturgoon</surname><given-names>AA</given-names></name></person-group>. <article-title>Functional analysis of the p53 codon 72 polymorphism in black South Africans with rheumatoid arthritis–a pilot study</article-title>. <source>Clin Rheumatol</source> <year>2010</year>; <volume>29</volume>: <fpage>1099</fpage>–<lpage>1105</lpage>.</citation></ref>
<ref id="bibr13-0961203311434941"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Assmann</surname><given-names>G</given-names></name><name><surname>Wagner</surname><given-names>AD</given-names></name><name><surname>Monika</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Single-nucleotide polymorphisms p53 G72C and Mdm2 T309G in patients with psoriasis, psoriatic arthritis, and SAPHO syndrome</article-title>. <source>Rheumatol Int</source> <year>2010</year>; <volume>30</volume>: <fpage>1273</fpage>–<lpage>1276</lpage>.</citation></ref>
<ref id="bibr14-0961203311434941"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Macchioni</surname><given-names>P</given-names></name><name><surname>Nicoli</surname><given-names>D</given-names></name><name><surname>Casali</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>The codon 72 polymorphic variants of p53 in Italian rheumatoid arthritis patients</article-title>. <source>Clin Exp Rheumatol</source> <year>2007</year>; <volume>25</volume>: <fpage>416</fpage>–<lpage>421</lpage>.</citation></ref>
<ref id="bibr15-0961203311434941"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>YR</given-names></name><name><surname>Ji</surname><given-names>JD</given-names></name><name><surname>Sohn</surname><given-names>J</given-names></name><name><surname>Song</surname><given-names>GG</given-names></name></person-group>. <article-title>p53 codon 72 polymorphism and rheumatoid arthritis</article-title>. <source>J Rheumatol</source> <year>2001</year>; <volume>28</volume>: <fpage>2392</fpage>–<lpage>2394</lpage>.</citation></ref>
<ref id="bibr16-0961203311434941"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Assmann</surname><given-names>G</given-names></name><name><surname>Voswinkel</surname><given-names>J</given-names></name><name><surname>Mueller</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Association of rheumatoid arthritis with Mdm2 SNP309 and genetic evidence for an allele-specific interaction between MDM2 and p53 P72R variants: a case control study</article-title>. <source>Clin Exp Rheumatol</source> <year>2009</year>; <volume>27</volume>: <fpage>615</fpage>–<lpage>619</lpage>.</citation></ref>
<ref id="bibr17-0961203311434941"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Harley</surname><given-names>JB</given-names></name><name><surname>Nath</surname><given-names>SK</given-names></name></person-group>. <article-title>Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility</article-title>. <source>Eur J Hum Genet</source> <year>2006</year>; <volume>14</volume>: <fpage>364</fpage>–<lpage>371</lpage>.</citation></ref>
<ref id="bibr18-0961203311434941"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Rho</surname><given-names>YH</given-names></name><name><surname>Choi</surname><given-names>SJ</given-names></name><name><surname>Ji</surname><given-names>JD</given-names></name><name><surname>Song</surname><given-names>GG</given-names></name></person-group>. <article-title>Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis</article-title>. <source>Rheumatol Int</source> <year>2006</year>; <volume>27</volume>: <fpage>157</fpage>–<lpage>161</lpage>.</citation></ref>
<ref id="bibr19-0961203311434941"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nath</surname><given-names>SK</given-names></name><name><surname>Harley</surname><given-names>JB</given-names></name><name><surname>Lee</surname><given-names>YH</given-names></name></person-group>. <article-title>Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis</article-title>. <source>Hum Genet</source> <year>2005</year>; <volume>118</volume>: <fpage>225</fpage>–<lpage>234</lpage>.</citation></ref>
<ref id="bibr20-0961203311434941"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name><name><surname>Schneider</surname><given-names>M</given-names></name><name><surname>Minder</surname><given-names>C</given-names></name></person-group>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source> <year>1997</year>; <volume>315</volume>: <fpage>629</fpage>–<lpage>634</lpage>.</citation></ref>
<ref id="bibr21-0961203311434941"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name></person-group>. <article-title>Quantifying heterogeneity in a meta-analysis</article-title>. <source>Stat Med</source> <year>2002</year>; <volume>21</volume>: <fpage>1539</fpage>–<lpage>1558</lpage>.</citation></ref>
<ref id="bibr22-0961203311434941"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>GD</given-names></name><name><surname>Phillips</surname><given-names>AN</given-names></name></person-group>. <article-title>Meta-analysis: principles and procedures</article-title>. <source>BMJ</source> <year>1997</year>; <volume>315</volume>: <fpage>1533</fpage>–<lpage>1537</lpage>.</citation></ref>
<ref id="bibr23-0961203311434941"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DerSimonian</surname><given-names>R</given-names></name><name><surname>Laird</surname><given-names>N</given-names></name></person-group>. <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source> <year>1986</year>; <volume>7</volume>: <fpage>177</fpage>–<lpage>188</lpage>.</citation></ref>
<ref id="bibr24-0961203311434941"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taubert</surname><given-names>H</given-names></name><name><surname>Thamm</surname><given-names>B</given-names></name><name><surname>Meye</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>The p53 status in juvenile chronic arthritis and rheumatoid arthritis</article-title>. <source>Clin Exp Immunol</source> <year>2000</year>; <volume>122</volume>: <fpage>264</fpage>–<lpage>269</lpage>.</citation></ref>
<ref id="bibr25-0961203311434941"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maalej</surname><given-names>A</given-names></name><name><surname>Petit-Teixeira</surname><given-names>E</given-names></name><name><surname>Michou</surname><given-names>L</given-names></name><name><surname>Rebai</surname><given-names>A</given-names></name><name><surname>Cornelis</surname><given-names>F</given-names></name><name><surname>Ayadi</surname><given-names>H</given-names></name></person-group>. <article-title>Association study of VDR gene with rheumatoid arthritis in the French population</article-title>. <source>Genes Immun</source> <year>2005</year>; <volume>6</volume>: <fpage>707</fpage>–<lpage>711</lpage>.</citation></ref>
<ref id="bibr26-0961203311434941"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lohmueller</surname><given-names>KE</given-names></name><name><surname>Pearce</surname><given-names>CL</given-names></name><name><surname>Pike</surname><given-names>M</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name></person-group>. <article-title>Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease</article-title>. <source>Nat Genet</source> <year>2003</year>; <volume>33</volume>: <fpage>177</fpage>–<lpage>182</lpage>.</citation></ref>
<ref id="bibr27-0961203311434941"><label>27.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>GD</given-names></name></person-group>. <article-title>Meta-Analysis. Potentials and promise</article-title>. <source>BMJ</source> <year>1997</year>; <volume>315</volume>: <fpage>1371</fpage>–<lpage>1374</lpage>.</citation></ref>
<ref id="bibr28-0961203311434941"><label>28.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dumont</surname><given-names>P</given-names></name><name><surname>Leu</surname><given-names>JI</given-names></name><name><surname>Della Pietra</surname><given-names>AC</given-names><suffix>III</suffix></name><name><surname>George</surname><given-names>DL</given-names></name><name><surname>Murphy</surname><given-names>M</given-names></name></person-group>. <article-title>The codon 72 polymorphic variants of p53 have markedly different apoptotic potential</article-title>. <source>Nat Genet</source> <year>2003</year>; <volume>33</volume>: <fpage>357</fpage>–<lpage>365</lpage>.</citation></ref>
<ref id="bibr29-0961203311434941"><label>29.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>WC</given-names></name><name><surname>Lee</surname><given-names>KM</given-names></name><name><surname>Lee</surname><given-names>BI</given-names></name><etal/></person-group>. <article-title>P53 genetic polymorphism of gastric cancer in Korea</article-title>. <source>Korean J Intern Med</source> <year>2006</year>; <volume>21</volume>: <fpage>28</fpage>–<lpage>32</lpage>.</citation></ref>
</ref-list>
</back>
</article>